Technology area: Biotechnology & Pharmaceuticals
41 pending office actions • 24 art units • 37 examiners • 0 of 41 (0%) have an AI response strategy ready • 41 patents granted in the last 365 days
Chugai Seiyaku Kabushiki Kaisha has 44 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 38 distinct examiners and 24 art units, indicating a multi-channel prosecution docket with substantial variation in examiner practice and technical assignment.
HABTE, KAHSAY is the busiest examiner, with 2 pending actions. That limited concentration suggests that portfolio management should not depend on a single examiner relationship. Counsel may instead organize work by recurring biotechnology claim issues, while tailoring arguments and evidence to the separate art units and examiner records.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (5%) |
| §103 only | 4 (10%) |
| §102 only | 1 (2%) |
| §112 only | 15 (37%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 4 (10%) |
| Multi-statute (no §101) | 14 (34%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANDSMAN, ROBERT S | 2 | 81.4% | +13.0% |
| RYAN, DOUGLAS CHARLES | 2 | 38.2% | +48.4% |
| SANG, HONG | 2 | 54.9% | +62.8% |
| MIDDLETON, DANAYA L | 2 | 49.5% | +48.8% |
| MOYER, DALE S | 1 | 81.6% | +16.3% |
| VOLKOV, ALEXANDER ALEXANDROVIC | 1 | 29.5% | +21.5% |
| BOSQUES, EDELMIRA | 1 | 62.8% | +19.7% |
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
| CHEONG, CHEOM-GIL | 1 | 64.1% | +53.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724369 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | KIEFER, DALTON EDWARD | — |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | LANDSMAN, ROBERT S | — |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 9d overdue |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 3d overdue |
| 18020656 | ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF | BERHANE, SELAM | 13d |
| 17616421 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND METHOD FOR PRODUCING ANTIGEN-BINDING MOLECULE OR PROTEIN | PLAYER, ROBERT AUSTIN | 27d |
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | — |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| 18859663 | TITLE OF INVENTION: PHARMACEUTICAL-PREPARATION-CONTAINING SYRINGE EQUIPPED WITH FILTER | BOSQUES, EDELMIRA | — |
| 18695400 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 53d overdue |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 3d overdue |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | RYAN, DOUGLAS CHARLES | 40d |
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | — |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| 18859663 | TITLE OF INVENTION: PHARMACEUTICAL-PREPARATION-CONTAINING SYRINGE EQUIPPED WITH FILTER | BOSQUES, EDELMIRA | — |
| 18827277 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | GEMBEH, SHIRLEY V | — |
| 18724369 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | KIEFER, DALTON EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1654 | 4 |
| 1647 | 3 |
| 1675 | 3 |
| 1641 | 3 |
| 1674 | 3 |
| 1677 | 2 |
| 1658 | 2 |
| 1624 | 2 |
| 1635 | 2 |
| 1646 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | 3656 | §102§103 | Non-Final OA | — | Pending | Jun 05, 2025 |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §102§103 | Non-Final OA | — | Pending | Mar 27, 2025 |
| 18859663 | TITLE OF INVENTION: PHARMACEUTICAL-PREPARATION-CONTAINING SYRINGE EQUIPPED WITH FILTER | BOSQUES, EDELMIRA | 3783 | §102§103 | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18827277 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | GEMBEH, SHIRLEY V | 1615 | §103DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18724369 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | KIEFER, DALTON EDWARD | 1652 | §112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18672417 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | CHEONG, CHEOM-GIL | 1645 | §103DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18656920 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | RAMACHANDRAN, UMAMAHESWARI | 1627 | DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18699488 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | MIKNIS, ZACHARY J | 1658 | §103§112DP | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18695400 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | BUNKER, AMY M | 1625 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18579949 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | RYAN, DOUGLAS CHARLES | 1635 | §112 | Final Rejection | 40d | Pending | Dec 22, 2023 |
| 18535310 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | SANG, HONG | 1646 | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18559876 | METHOD FOR PREDICTING IN VIVO PHARMACOKINETICS OF MOLECULE | MONTGOMERY, ANN Y | 1678 | §112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | LANDSMAN, ROBERT S | 1647 | §112 | Final Rejection | — | Pending | Nov 06, 2023 |
| 18289451 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | MARTINEZ, TARA L | 1654 | §112Other | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18286471 | ANTI-C1s ANTIBODY | XIAO, YAN | 1642 | §112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 1624 | §103§112 | Final Rejection | 9d overdue | Pending | Aug 30, 2023 |
| 18270793 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | BAHTA, MEDHANIT W | 1692 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18269099 | ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY | MACFARLANE, STACEY NEE | 1675 | §112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18034424 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | BEANE, RANDALL L | 1654 | §102§103§112Other | Final Rejection | — | Pending | Apr 28, 2023 |
| 18034429 | THERAPEUTIC AGENT FOR PERIPARTUM CARDIOMYOPATHY | ALLEN, MARIANNE P | 1647 | §102§103 | Final Rejection | — | Pending | Apr 28, 2023 |
| 18138888 | TARGET TISSUE-SPECIFIC ANTIGEN-BINDING MOLECULE | EVANS, CHRISTOPHER RYAN | 1677 | §102§103Other | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18298743 | METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18023038 | HETERODIMER FC POLYPEPTIDE | MIDDLETON, DANAYA L | 1674 | §101§102§112DP | Final Rejection | — | Pending | Feb 24, 2023 |
| 18022342 | HETERODIMER FC POLYPEPTIDE | MIDDLETON, DANAYA L | 1674 | §102§112DP | Final Rejection | — | Pending | Feb 21, 2023 |
| 18020656 | ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF | BERHANE, SELAM | 1675 | §102§112 | Non-Final OA | 13d | Pending | Feb 10, 2023 |
| 18018460 | METHOD FOR MEASURING PHARMACOKINETICS OF AGENT LABELED WITH NON-RADIOACTIVE SUBSTANCE | XU, XIAOYUN | 1797 | §103 | Final Rejection | — | Pending | Jan 27, 2023 |
| 18157320 | ANTI-C5 ANTIBODIES AND METHODS OF USE | DIBRINO, MARIANNE | 1641 | §102§112Other | Non-Final OA | — | Pending | Jan 20, 2023 |
| 17954477 | PHARMACEUTICAL COMPOSITION | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Sep 28, 2022 |
| 17797540 | METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | 28d overdue | Pending | Aug 04, 2022 |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 44d overdue | Pending | Jun 23, 2022 |
| 17773733 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | SABILA, MERCY HELLEN | 1654 | §112 | Final Rejection | 20d | Pending | May 02, 2022 |
| 17716467 | ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN | LI, RUIXIANG | 1674 | §103 | Final Rejection | 73d overdue | Pending | Apr 08, 2022 |
| 17587465 | MOLECULE SPECIFICALLY ACTING IN A TISSUE WHERE A CELL DEATH IS BEING OBSERVED | PATTERSON, SARAH COOPER | 1675 | §112 | Final Rejection | — | Pending | Jan 28, 2022 |
| 17625868 | ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR | CUNNINGCHEN, KATHLEEN MARY | 1600 | §103§112 | Non-Final OA | — | Pending | Jan 10, 2022 |
| 17616421 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND METHOD FOR PRODUCING ANTIGEN-BINDING MOLECULE OR PROTEIN | PLAYER, ROBERT AUSTIN | 1686 | §101§103§112 | Final Rejection | 27d | Pending | Dec 03, 2021 |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 1635 | §102§103§112 | Final Rejection | 3d overdue | Pending | Jun 24, 2021 |
| 17266029 | METHOD FOR CULTURING CANCER TISSUE OR TISSUE ANALOGOUS TO CANCER TISSUE | IVICH, FERNANDO NMN | 1678 | §102 | Final Rejection | — | Pending | Feb 04, 2021 |
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 1646 | §112 | Final Rejection | 53d overdue | Pending | Jan 08, 2021 |
| 16081522 | PRODUCTION METHOD FOR NONCYCLIC PEPTIDE-NUCLEIC ACID COMPLEX HAVING, AT N-TERMINAL, AMINO ACID WITH THIOL GROUP NEAR AMINO GROUP, LIBRARY THEREOF, AND CYCLIC PEPTIDE-NUCLEIC ACID COMPLEX LIBRARY DERIVED FROM SAME | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Jul 08, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChugai Seiyaku Kabushiki Kaisha has 41 pending office actions as of October 2026, spread across 24 art units and 37 examiners.
Robert S Landsman has the most, with 2 of Chugai Seiyaku Kabushiki Kaisha's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
